Allison Dorval's Insider Trades & SAST Disclosures
Allison Dorval's most recent trade in Verve Therapeutics Inc was a trade of 11,250 Common Stock done . Disclosure was reported to the exchange on April 1, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Allison Dorval.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Verve Therapeutics Inc | Allison Dorval | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2025 | 11,250 | 16,630 | - | - | Common Stock | |
| Verve Therapeutics Inc | Allison Dorval | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2025 | 11,250 | 33,750 | - | - | Restricted Stock Units | |
| Verve Therapeutics Inc | Allison Dorval | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 4.15 per share. | 01 Apr 2025 | 3,350 | 13,280 | - | 4.2 | 13,903 | Common Stock |
| Verve Therapeutics Inc | Allison Dorval | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jan 2025 | 258,000 | 258,000 | - | - | Stock Option (right to buy) | |
| Verve Therapeutics Inc | Allison Dorval | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jan 2025 | 75,000 | 75,000 | - | - | Stock Option (right to buy) | |
| Verve Therapeutics Inc | Allison Dorval | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jan 2025 | 45,000 | 45,000 | - | - | Restricted Stock Units | |
| Verve Therapeutics Inc | Dorval Allison | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Nov 2024 | 1,875 | 1,875 | - | - | Restricted Stock Units | |
| Verve Therapeutics Inc | Dorval Allison | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Nov 2024 | 1,875 | 5,935 | - | - | Common Stock | |
| Verve Therapeutics Inc | Allison Dorval | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 5.64 per share. | 29 Nov 2024 | 555 | 5,380 | - | 5.6 | 3,130 | Common Stock |
| Puma Biotechnology Inc | Allison Dorval | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2024 | 27,000 | 60,000 (0%) | 0% | 0 | Common Stock | |
| Puma Biotechnology Inc | Allison Dorval | Director | Sale of securities on an exchange or to another person at price $ 3.37 per share. | 13 Jun 2024 | 11,000 | 33,000 (0%) | 0% | 3.4 | 37,096 | Common Stock |
| Jade Biosciences Inc | Allison Dorval | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 12,500 | 12,500 | - | - | Stock Option (Right to Buy) | |
| Verve Therapeutics Inc | Dorval Allison | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 180,000 | 180,000 | - | - | Stock Option (right to buy) | |
| Verve Therapeutics Inc | Dorval Allison | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 45,000 | 45,000 | - | - | Restricted Stock Units | |
| Puma Biotechnology Inc | Allison Dorval | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 27,000 | 44,000 (0%) | 0% | 0 | Common Stock | |
| Puma Biotechnology Inc | Allison Dorval | Director | Sale of securities on an exchange or to another person at price $ 3.45 per share. | 13 Jun 2023 | 10,000 | 17,000 (0%) | 0% | 3.5 | 34,500 | Common Stock |
| Jade Biosciences Inc | Allison Dorval | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 12,500 | 12,500 | - | - | Stock Option (Right to Buy) | |
| Verve Therapeutics Inc | Allison Dorval | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2023 | 182,800 | 182,800 | - | - | Stock Option (right to buy) | |
| Verve Therapeutics Inc | Allison Dorval | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Nov 2022 | 1,875 | 2,740 | - | - | Common Stock | |
| Verve Therapeutics Inc | Allison Dorval | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Nov 2022 | 1,875 | 5,625 | - | - | Restricted Stock Units | |
| Verve Therapeutics Inc | Allison Dorval | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 22.10 per share. | 29 Nov 2022 | 554 | 2,186 | - | 22.1 | 12,243 | Common Stock |
| Jade Biosciences Inc | Allison Dorval | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2022 | 12,500 | 12,500 | - | - | Stock Option (Right to Buy) | |
| Puma Biotechnology Inc | Allison Dorval | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2022 | 27,000 | 27,000 (0%) | 0% | 0 | Common Stock | |
| Verve Therapeutics Inc | Allison Dorval | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2022 | 60,000 | 60,000 | - | - | Stock Option (right to buy) | |
| Verve Therapeutics Inc | Allison Dorval | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Nov 2021 | 135,000 | 135,000 | - | - | Stock Option (right to buy) | |
| Verve Therapeutics Inc | Allison Dorval | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Nov 2021 | 7,500 | 7,500 | - | - | Restricted Stock Units | |
| Puma Biotechnology Inc | Allison Dorval | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jul 2021 | 108,721 | 108,721 | - | - | STOCK OPTION (RIGHT TO BUY) | |
| Jade Biosciences Inc | Allison Dorval | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jul 2021 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Voyager Therapeutics Inc | Allison Dorval | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Mar 2021 | 30,000 | 109,894 (0%) | 0% | 0 | Common Stock | |
| Voyager Therapeutics Inc | Allison Dorval | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2021 | 68,000 | 68,000 | - | - | Stock Option (Right to Buy) | |
| Voyager Therapeutics Inc | Allison Dorval | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2021 | 34,000 | 79,894 (0%) | 0% | 0 | Common Stock | |
| Voyager Therapeutics Inc | Allison Dorval | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 7.55 per share. | 11 Feb 2021 | 3,186 | 45,894 (0%) | 0% | 7.5 | 24,054 | Common Stock |
| Voyager Therapeutics Inc | Allison Dorval | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 8.62 per share. | 12 Jan 2021 | 2,942 | 49,080 (0%) | 0% | 8.6 | 25,360 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges